Literature DB >> 16563707

Clinical pharmacokinetics of voriconazole.

Dominique Levêque1, Yasmine Nivoix, François Jehl, Raoul Herbrecht.   

Abstract

This review presents the published clinical pharmacokinetic data for the antifungal agent voriconazole. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16563707     DOI： 10.1016/j.ijantimicag.2006.01.003

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  38 in total

Review 1.  Azole interactions with multidrug therapy in pediatric oncology.

Authors:  Antonio Ruggiero; Roberta Arena; Andrea Battista; Daniela Rizzo; Giorgio Attinà; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

2.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

3.  Relationship of blood level and susceptibility in voriconazole treatment of histoplasmosis.

Authors:  Alison Freifeld; Sandra Arnold; Winnie Ooi; Fabian Chen; Thomas Meyer; L Joseph Wheat; Melinda Smedema; Ann Lemonte; Patricia Connolly
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

4.  Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.

Authors:  Kelong Han; Robert Bies; Heather Johnson; Blair Capitano; Raman Venkataramanan
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

5.  Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.

Authors:  I Fan Kuo; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2009-11

6.  Correlation of serum galactomannan antigen with diagnosis and response to voriconazole in orbital/sino-orbital invasive aspergillosis.

Authors:  J Navarosh; N Pushker; I Xess; L Singh; M S Bajaj; S Kashyap; A Thakar
Journal:  Int Ophthalmol       Date:  2021-06-10       Impact factor: 2.031

7.  Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies.

Authors:  K Nomura; Y Fujimoto; Y Kanbayashi; K Ikawa; M Taniwaki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-18       Impact factor: 3.267

8.  Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis.

Authors:  Daoud Al-Badriyeh; Chin Fen Neoh; Kay Stewart; David C M Kong
Journal:  Clin Ophthalmol       Date:  2010-05-06

Review 9.  Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.

Authors:  Rajendra S Kadam; Johannes N Van Den Anker
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

Review 10.  Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.

Authors:  Florence Ader; Anne-Lise Bienvenu; Blandine Rammaert; Saad Nseir
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.